180 related articles for article (PubMed ID: 37304043)
21. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.
Gallardo M; Munk MR; Kurmann T; De Zanet S; Mosinska A; Karagoz IK; Zinkernagel MS; Wolf S; Sznitman R
Ophthalmol Retina; 2021 Jul; 5(7):604-624. PubMed ID: 33971352
[TBL] [Abstract][Full Text] [Related]
22. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
23. Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial.
Riedl S; Vogl WD; Waldstein SM; Schmidt-Erfurth U; Bogunović H
Ophthalmol Retina; 2022 Apr; 6(4):291-297. PubMed ID: 34922038
[TBL] [Abstract][Full Text] [Related]
24. Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.
Sodhi SK; Pereira A; Oakley JD; Golding J; Trimboli C; Russakoff DB; Choudhry N
PLoS One; 2022; 17(2):e0262111. PubMed ID: 35157713
[TBL] [Abstract][Full Text] [Related]
25. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
Waldstein SM; Wright J; Warburton J; Margaron P; Simader C; Schmidt-Erfurth U
Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
[TBL] [Abstract][Full Text] [Related]
27. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.
Khurana RN; Kunimoto D; Yoon YH; Wykoff CC; Chang A; Maturi RK; Agostini H; Souied E; Chow DR; Lotery AJ; Ohji M; Bandello F; Belfort R; Li XY; Jiao J; Le G; Kim K; Schmidt W; Hashad Y;
Ophthalmology; 2021 Jul; 128(7):1027-1038. PubMed ID: 33221326
[TBL] [Abstract][Full Text] [Related]
28. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
29. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.
Schmidt-Erfurth U; Vogl WD; Jampol LM; Bogunović H
Ophthalmology; 2020 Sep; 127(9):1211-1219. PubMed ID: 32327254
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
[TBL] [Abstract][Full Text] [Related]
31. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
32. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.
Zarbin MA; Hill L; Maunz A; Gliem M; Stoilov I
Br J Ophthalmol; 2022 Nov; 106(11):1561-1566. PubMed ID: 34039560
[TBL] [Abstract][Full Text] [Related]
33. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
Jackson TL; Dugel PU; Bebchuk JD; Smith KR; Petrarca R; Slakter JS; Jaffe GJ; Nau JA;
Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
[TBL] [Abstract][Full Text] [Related]
34. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
Jackson TL; Slakter J; Buyse M; Wang K; Dugel PU; Wykoff CC; Boyer DS; Gerometta M; Baldwin ME; Price CF;
Ophthalmology; 2023 Jun; 130(6):588-597. PubMed ID: 36754174
[TBL] [Abstract][Full Text] [Related]
35. OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study.
Nassisi M; Lei J; Abdelfattah NS; Karamat A; Balasubramanian S; Fan W; Uji A; Marion KM; Baker K; Huang X; Morgenthien E; Sadda SR
Ophthalmology; 2019 Dec; 126(12):1667-1674. PubMed ID: 31281056
[TBL] [Abstract][Full Text] [Related]
36. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
38. Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration from a Phase III Clinical Trial.
Yordi S; Cakir Y; Cetin H; Talcott KE; Srivastava SK; Hu J; Ehlers JP
Ophthalmol Retina; 2024 Feb; ():. PubMed ID: 38360182
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Mathew R; Richardson M; Sivaprasad S
Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
Inan S; Baysal Z; Inan UU
Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
